← Back to Treatments
🏅 FDA Orphan Designation

Hyftor

SIROLIMUS

Manufacturer: Nobelpharma America, LLC

Indicated for:
Multiple paragangliomas associated with polycythemiaOrphan

FDA-Approved Indications (1)

treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older

Indications & Usage

1 INDICATIONS AND USAGE HYFTOR is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. ( 1 )

💙 Support Programs

View all →
Temsirolimus
Pfizer
Apply ↗
Hyftor
Nobelpharma America, LLC

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.